Compare CNNE & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | OABI |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 686.6M | 742.4M |
| IPO Year | 2017 | 2021 |
| Metric | CNNE | OABI |
|---|---|---|
| Price | $17.52 | $5.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $17.25 | $8.33 |
| AVG Volume (30 Days) | 445.4K | ★ 1.4M |
| Earning Date | 11-09-2026 | 10-30-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | ★ 6.56 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $499,700,000.00 | $18,666,000.00 |
| Revenue This Year | N/A | $94.10 |
| Revenue Next Year | $0.87 | $30.33 |
| P/E Ratio | $147.75 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $1.35 |
| 52 Week High | $18.48 | $5.43 |
| Indicator | CNNE | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 60.09 |
| Support Level | $15.08 | $4.43 |
| Resistance Level | N/A | $5.30 |
| Average True Range (ATR) | 0.49 | 0.38 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 62.37 | 85.00 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.